Outlook Therapeutics, Inc. (OTLK) 10-Year Financial Performance & Capital Metrics

OTLK • • Industrial / General

HealthcareBiotechnologyAutoimmune & Inflammatory DiseasesOphthalmology & Ocular Diseases

AboutOutlook Therapeutics, Inc., a late clinical-stage biopharmaceutical company, focuses on developing and commercializing monoclonal antibodies for various ophthalmic indications. Its lead product candidate is ONS-5010, an ophthalmic formulation of bevacizumab product candidate that is in Phase-III clinical trial for the treatment of wet age-related macular degeneration and other retina diseases. Outlook Therapeutics, Inc. has collaboration and license agreements with IPCA Laboratories Limited; Laboratorios Liomont, S.A. de C.V.; BioLexis Pte. Ltd.; and Zhejiang Huahai Pharmaceutical Co., Ltd. The company was formerly known as Oncobiologics, Inc. and changed its name to Outlook Therapeutics, Inc. in November 2018. Outlook Therapeutics, Inc. was incorporated in 2010 and is based in Iselin, New Jersey.Show more

Revenue $1413.54B
EBITDA -$67061.67B -93675651.7%
Net Income -$62424.86B -82827746.4%
EPS (Diluted) -1.79 +55.9%
Gross Margin 4.05%
EBITDA Margin -4744.25%
Operating Margin -4744.25%
Net Margin -4416.22%
ROE -
ROIC -
Debt/Equity -
Interest Coverage -236.86 -942.9%

Technical Analysis

Key Insights

Based on financial data analysis

✓Strengths

No significant strengths identified

✗Weaknesses

✗Negative free cash flow
✗Weak momentum: RS Rating 4 (bottom 4%)
✗Shares diluted 37.3% in last year
✗Trading more than 30% below 52-week high
✗Low asset turnover indicates capital-intensive operations

Price & Volume

Loading chart...

Growth Metrics

Revenue CAGR

10Y249.36%

5Y-

3Y-

TTM-

Profit (Net Income) CAGR

10Y-

5Y-

3Y-

TTM53.81%

EPS CAGR

10Y-

5Y-

3Y-

TTM90.51%

ROCE

10Y Avg-71076.28%

5Y Avg-114371.18%

3Y Avg-342086.28%

Latest-

Peer Comparison

Ophthalmology & Ocular Diseases

Name	Market Cap	Current Price	P/E Ratio	Revenue Growth 1Y	Net Margin	ROE	FCF Yield	Debt/Equity
KPRXKiora Pharmaceuticals, Inc.	8.05M	2.19	2.52		22.47%	-38.12%	100%	0.00
KALAKALA BIO, Inc.	16.74M	0.60	-0.09		-141.11%	-388.29%		2.62
CLSDClearside Biomedical, Inc.	5.81M	1.11	-0.16	-79.77%	-7.81%
OTLKOutlook Therapeutics, Inc.	33.47M	0.52	-0.29		-25.93%
ADVMAdverum Biotechnologies, Inc.	96.26M	4.36	-0.66	-72.22%	-130.93%	-189.84%		1.30
IRDOpus Genetics, Inc.	143.45M	2.08	-0.97	-42.3%	-466.09%	-11.43%
SKYESkye Bioscience, Inc.	30.87M	0.96	-1.32			-156.01%		0.01
ALDXAldeyra Therapeutics, Inc.	265.32M	4.41	-4.69			-87.71%		0.22

Profit & Loss

	Sep 2016	Sep 2017	Sep 2018	Sep 2019	Sep 2020	Sep 2021	Sep 2022	Sep 2023	Sep 2024	Sep 2025
Sales/Revenue+	2.98M	3.81M	3.09M	8.15M	0	0	0	0	0	1.41T
Revenue Growth %	-0.43%	0.28%	-0.19%	1.64%	-1%	-	-	-	-	-
Cost of Goods Sold+	0	23.81M	18.5M	23.8M	554.07K	262.14K	204.69K	44.19K	113.86K	1.36T
COGS % of Revenue	-	6.25%	5.99%	2.92%	-	-	-	-	-	0.96%
Gross Profit+	0	0	0	-15.66M	-554.07K	-262.14K	-204.69K	-44.19K	-113.86K	57.2B
Gross Margin %	-	-	-	-1.92%	-	-	-	-	-	0.04%
Gross Profit Growth %	-	-	-	-	0.96%	0.53%	0.22%	0.78%	-1.58%	502420.66%
Operating Expenses+	21.56M	39.69M	32.73M	44.45M	34.42M	51.73M	62.87M	53.13M	71.7M	67.12T
OpEx % of Revenue	7.24%	10.41%	10.6%	5.46%	-	-	-	-	-	47.48%
Selling, General & Admin	21.56M	15.88M	14.23M	9.37M	9.97M	12.77M	20.74M	26.67M	29.94M	39.94T
SG&A % of Revenue	7.24%	4.17%	4.61%	1.15%	-	-	-	-	-	28.25%
Research & Development	32.76M	23.81M	18.5M	23.8M	26.34M	38.96M	42.33M	26.45M	41.76M	27.18T
R&D % of Revenue	10.99%	6.25%	5.99%	2.92%	-	-	-	-	-	19.23%
Other Operating Expenses	0	-23.81M	0	11.27M	-1.9M	0	-205K	0	0	0
Operating Income+	-51.35M	-35.88M	-29.64M	-36.3M	-36.84M	-51.73M	-63.07M	-53.13M	-71.7M	-67.06T
Operating Margin %	-17.23%	-9.41%	-9.6%	-4.46%	-	-	-	-	-	-47.44%
Operating Income Growth %	-0.1%	0.3%	0.17%	-0.22%	-0.01%	-0.4%	-0.22%	0.16%	-0.35%	-935269.02%
EBITDA+	-48.95M	-33.19M	-26.59M	-32.94M	-36.29M	-51.46M	-62.87M	-53.08M	-71.59M	-67.06T
EBITDA Margin %	-16.43%	-8.71%	-8.61%	-4.04%	-	-	-	-	-	-47.44%
EBITDA Growth %	-0.09%	0.32%	0.2%	-0.24%	-0.1%	-0.42%	-0.22%	0.16%	-0.35%	-936756.52%
D&A (Non-Cash Add-back)	2.39M	2.69M	3.05M	3.36M	554.07K	262.14K	204.69K	44.19K	113.86K	0
EBIT	-51.35M	-32.72M	-29.85M	-34.47M	-36.76M	-51.73M	-64.56M	-57.42M	-72.21M	0
Net Interest Income+	-1.85M	-5.63M	-3.89M	-3.47M	-1.76M	-936.13K	-1.49M	-1.56M	-2.25M	0
Interest Income	0	0	0	0	0	0	0	0	906.15K	-89.74B
Interest Expense	1.85M	5.63M	3.89M	3.47M	1.76M	936.13K	1.49M	1.56M	3.16M	283.13B
Other Income/Expense	-1.85M	-2.47M	-4.1M	-1.64M	-1.67M	-1.43M	-2.98M	-5.85M	-3.66M	3.08T
Pretax Income+	-53.2M	-38.35M	-33.74M	-37.94M	-38.51M	-53.16M	-66.05M	-58.98M	-75.36M	-63.98T
Pretax Margin %	-17.85%	-10.06%	-10.93%	-4.66%	-	-	-	-	-	-45.26%
Income Tax+	103K	501.5K	-3.65M	-3.41M	-3.27M	2K	2.8K	2.8K	2.8K	-1.55T
Effective Tax Rate %	1%	1.01%	0.89%	0.91%	0.92%	1%	1%	1%	1%	0.98%
Net Income+	-53.3M	-38.85M	-30.09M	-34.52M	-35.24M	-53.16M	-66.05M	-58.98M	-75.37M	-62.42T
Net Margin %	-17.89%	-10.19%	-9.74%	-4.24%	-	-	-	-	-	-44.16%
Net Income Growth %	-0.12%	0.27%	0.23%	-0.15%	-0.02%	-0.51%	-0.24%	0.11%	-0.28%	-828277.46%
Net Income (Continuing)	-53.3M	-38.85M	-30.09M	-34.52M	-35.24M	-53.16M	-66.05M	-58.98M	-75.37M	0
Discontinued Operations	0	0	0	0	0	0	0	0	0	0
Minority Interest	0	0	0	0	0	0	0	0	0	0
EPS (Diluted)+	-587.20	-288.00	-85.00	-39.60	-13.47	-6.96	-6.23	-4.72	-4.06	-1.79
EPS Growth %	-0.04%	0.51%	0.7%	0.53%	0.66%	0.48%	0.1%	0.24%	0.14%	0.56%
EPS (Basic)	-587.20	-267.20	-194.80	-39.60	-13.47	-6.96	-6.23	-4.72	-4.06	-1.79
Diluted Shares Outstanding	107.58K	150.26K	354.03K	909.59K	3.63M	7.63M	10.6M	12.51M	18.55M	25.48M
Basic Shares Outstanding	90K	150.14K	154K	909.59K	3.63M	7.63M	10.6M	12.51M	18.55M	34.8M
Dividend Payout Ratio	-	-	-	-	-	-	-	-	-	-

Balance Sheet

	Sep 2016	Sep 2017	Sep 2018	Sep 2019	Sep 2020	Sep 2021	Sep 2022	Sep 2023	Sep 2024	Sep 2025
Total Current Assets+	5.68M	3.9M	3.3M	13.5M	17.94M	21.51M	27.52M	30.98M	27.42M	17.39T
Cash & Short-Term Investments	2.35M	3.19M	1.72M	8.02M	12.54M	14.48M	17.4M	23.39M	14.93M	8.08T
Cash Only	2.35M	3.19M	1.72M	8.02M	12.54M	14.48M	17.4M	23.39M	14.93M	8.08T
Short-Term Investments	0	0	0	0	0	0	0	0	0	0
Accounts Receivable	0	0	0	0	0	0	0	0	0	1.49T
Days Sales Outstanding	-	-	-	-	-	-	-	-	-	384.99
Inventory	0	0	0	0	0	0	0	0	0	3.34T
Days Inventory Outstanding	-	-	-	-	-	-	-	-	-	898.39
Other Current Assets	0	0	0	1.7M	0	324	0	7.59M	12.49M	4.48T
Total Non-Current Assets+	18.03M	16.83M	18.98M	3.63M	1.79M	1.3M	1.01M	1.32M	1.41M	1.2T
Property, Plant & Equipment	16.96M	16.09M	18.49M	3.18M	494.24K	275.05K	70.36K	26.17K	274.64K	225.51B
Fixed Asset Turnover	0.18x	0.24x	0.17x	2.56x	-	-	-	-	-	6.27x
Goodwill	0	0	0	0	0	0	0	0	0	0
Intangible Assets	0	0	0	0	0	0	0	0	0	0
Long-Term Investments	216.09K	0	0	0	900K	853.66K	804.93K	793.93K	693.19K	0
Other Non-Current Assets	852.8K	740.36K	491.04K	457.48K	394.45K	174.59K	132.01K	501.3K	439.28K	969.71B
Total Assets+	23.71M	20.73M	22.28M	17.13M	19.73M	22.81M	28.53M	32.3M	28.82M	18.58T
Asset Turnover	0.13x	0.18x	0.14x	0.48x	-	-	-	-	-	0.08x
Asset Growth %	1.04%	-0.13%	0.07%	-0.23%	0.15%	0.16%	0.25%	0.13%	-0.11%	644764.77%
Total Current Liabilities+	20.44M	28.74M	32.04M	20.29M	15.89M	6.75M	19.73M	46.73M	42.55M	45.81T
Accounts Payable	5.07M	10.95M	3.61M	2.28M	2.39M	2.2M	3.49M	6.57M	7.97M	10.19T
Days Payables Outstanding	-	167.93	71.2	34.93	1.58K	3.06K	6.23K	54.31K	25.55K	2.74K
Short-Term Debt	5.2M	4.67M	17.86M	11.34M	3.66M	904.2K	10.92M	35.55M	29.44M	58.9B
Deferred Revenue (Current)	1000K	1000K	1000K	0	0	0	0	0	0	0
Other Current Liabilities	2.16M	3.69M	4.17M	5.56M	5.06M	2.83M	1.45M	1.83M	0	45.76T
Current Ratio	0.28x	0.14x	0.10x	0.67x	1.13x	3.19x	1.39x	0.66x	0.64x	0.38x
Quick Ratio	0.28x	0.14x	0.10x	0.67x	1.13x	3.19x	1.39x	0.66x	0.64x	0.31x
Cash Conversion Cycle	-	-	-	-	-	-	-	-	-	-1.46K
Total Non-Current Liabilities+	8.47M	22.72M	11.05M	7.61M	1.02M	11.45M	61.41K	6.22K	59.35M	4.96T
Long-Term Debt	2.23M	13.38M	98.49K	50.28K	904.2K	10.89M	0	0	0	188.8B
Capital Lease Obligations	320.74K	28.07K	3.45M	3.37M	42.48K	43.01K	4.27K	0	246.92K	0
Deferred Tax Liabilities	0	2.27M	3.45M	0	0	0	0	0	0	0
Other Non-Current Liabilities	761.33K	4.84M	4.74M	4.2M	70.77K	522.92K	57.14K	6.22K	59.1M	4.77T
Total Liabilities	28.91M	51.46M	43.09M	27.9M	16.91M	18.2M	19.79M	46.74M	101.9M	50.77T
Total Debt+	8.73M	18.42M	21.93M	14.95M	8.8M	11.9M	10.96M	35.56M	29.74M	247.7B
Net Debt	6.38M	15.23M	20.21M	6.93M	-3.74M	-2.57M	-6.44M	12.16M	14.81M	-7.84T
Debt / Equity	-	-	-	-	3.11x	2.58x	1.25x	-	-	-
Debt / EBITDA	-	-	-	-	-	-	-	-	-	-
Net Debt / EBITDA	-	-	-	-	-	-	-	-	-	-
Interest Coverage	-27.73x	-6.38x	-7.62x	-10.47x	-20.98x	-55.26x	-42.41x	-34.06x	-22.71x	-236.86x
Total Equity+	-5.2M	-30.73M	-20.81M	-10.77M	2.83M	4.61M	8.74M	-14.44M	-73.08M	-32.19T
Equity Growth %	0.78%	-4.91%	0.32%	0.48%	1.26%	0.63%	0.9%	-2.65%	-4.06%	-440464.22%
Book Value per Share	-48.34	-204.49	-58.78	-11.84	0.78	0.60	0.82	-1.15	-3.94	-999999.00
Total Shareholders' Equity	-5.2M	-30.73M	-20.81M	-10.77M	2.83M	4.61M	8.74M	-14.44M	-73.08M	-32.19T
Common Stock	228.03K	249.34K	722.2K	286.1K	1.27M	1.76M	2.27M	2.6M	239.06K	538.87B
Retained Earnings	-147.39M	-186.22M	-216.31M	-254.48M	-289.72M	-342.88M	-408.94M	-467.92M	-543.28M	-605.71T
Treasury Stock	0	0	0	0	0	0	0	0	0	0
Accumulated OCI	-5.96M	-8.64M	190.76M	0	-19.73T	-22.81T	417.67M	-32.3T	0	0
Minority Interest	0	0	0	0	0	0	0	0	0	0

Cash Flow

	Sep 2016	Sep 2017	Sep 2018	Sep 2019	Sep 2020	Sep 2021	Sep 2022	Sep 2023	Sep 2024	Sep 2025
Cash from Operations+	-45.48M	-15.51M	-33.04M	-32.29M	-31.79M	-54.25M	-56.67M	-42.97M	-68.79M	-51.83T
Operating CF Margin %	-15.26%	-4.07%	-10.7%	-3.96%	-	-	-	-	-	-36.67%
Operating CF Growth %	-0.66%	0.66%	-1.13%	0.02%	0.02%	-0.71%	-0.04%	0.24%	-0.6%	-753401.1%
Net Income	-53.33M	-38.85M	-46.11M	-34.52M	-35.24M	-53.16M	-66.05M	-58.98M	-75.37M	-62.42T
Depreciation & Amortization	2.39M	2.69M	-3.05M	3.36M	554.07K	262.14K	204.69K	44.19K	113.86K	117.05B
Stock-Based Compensation	12.45M	8.57M	1.99M	1.31M	2.81M	4.89M	7.71M	5.55M	5.39M	8.9T
Deferred Taxes	13.65K	-3.1M	20.15M	9.44M	2.24M	498.49K	0	0	0	0
Other Non-Cash Items	13.46K	4.01M	7.68M	1.31M	-881.33K	341.55K	3.15M	5.66M	4.09M	1.58T
Working Capital Changes	-7.02M	11.16M	-13.68M	-13.19M	-1.27M	-7.08M	-1.68M	4.75M	-3.02M	0
Change in Receivables	20K	0	0	0	0	0	0	0	0	-1.49T
Change in Inventory	-221.36K	0	0	0	0	0	0	0	0	-3.34T
Change in Payables	-5.33M	5.73M	-6.71M	-1.33M	-1.49M	-198.47K	1.3M	3.08M	1.39M	1.67T
Cash from Investing+	-1.1M	-292.09K	-2.78M	-437.31K	-900K	0	0	0	0	0
Capital Expenditures	-1.1M	-292.09K	-2.78M	-437.31K	0	0	0	0	0	0
CapEx % of Revenue	0.37%	0.08%	0.9%	0.05%	-	-	-	-	-	-
Acquisitions	-	-	-	-	-	-	-	-	-	-
Investments	-	-	-	-	-	-	-	-	-	-
Other Investing	0	0	0	0	900K	0	0	0	0	0
Cash from Financing+	39.86M	16.63M	34.35M	39.03M	37.21M	56.19M	59.59M	48.97M	60.33M	44.98T
Debt Issued (Net)	-	-	-	-	-	-	-	-	-	-
Equity Issued (Net)	-	-	-	-	-	-	-	-	-	-
Dividends Paid	0	-16.98B	-1.89T	0	0	0	0	0	0	0
Share Repurchases	-	-	-	-	-	-	-	-	-	-
Other Financing	-6.21K	16.99B	-1.09M	4.35K	1.14M	3.59M	-394.15K	-823.89K	0	44.98T
Net Change in Cash	-	-	-	-	-	-	-	-	-	-
Free Cash Flow+	-46.58M	-15.8M	-35.82M	-32.73M	-31.79M	-54.25M	-56.67M	-42.97M	-68.79M	-51.83T
FCF Margin %	-15.63%	-4.14%	-11.6%	-4.02%	-	-	-	-	-	-36.67%
FCF Growth %	-0.28%	0.66%	-1.27%	0.09%	0.03%	-0.71%	-0.04%	0.24%	-0.6%	-753401.1%
FCF per Share	-432.98	-105.13	-101.18	-35.98	-8.76	-7.11	-5.34	-3.44	-3.71	-999999.00
FCF Conversion (FCF/Net Income)	0.85x	0.40x	1.10x	0.94x	0.90x	1.02x	0.86x	0.73x	0.91x	0.83x
Interest Paid	2.06M	1.34M	109.98K	2.79M	913.97K	46.24K	1.56M	1.16M	475K	0
Taxes Paid	3K	1.5K	0	0	0	0	0	0	0	0

Key Ratios

Metric	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025
Return on Equity (ROE)	-	-	-	-	-1246.96%	-1430.46%	-990.02%	-	-	-
Return on Invested Capital (ROIC)	-3267.24%	-	-	-	-	-6926.23%	-2184.82%	-342086.28%	-	-
Gross Margin	-	-	-	-192.23%	-	-	-	-	-	4.05%
Net Margin	-1788.66%	-1019.12%	-974.48%	-423.82%	-	-	-	-	-	-4416.22%
Debt / Equity	-	-	-	-	3.11x	2.58x	1.25x	-	-	-
Interest Coverage	-27.73x	-6.38x	-7.62x	-10.47x	-20.98x	-55.26x	-42.41x	-34.06x	-22.71x	-236.86x
FCF Conversion	0.85x	0.40x	1.10x	0.94x	0.90x	1.02x	0.86x	0.73x	0.91x	0.83x
Revenue Growth	-42.9%	27.92%	-18.99%	163.8%	-100%	-	-	-	-	-

Frequently Asked Questions

Growth & Financials

Outlook Therapeutics, Inc. (OTLK) reported $1.7M in revenue for fiscal year 2025. This represents a 81% decrease from $9.1M in 2014.

Outlook Therapeutics, Inc. (OTLK) grew revenue by 0.0% over the past year. Growth has been modest.

Outlook Therapeutics, Inc. (OTLK) reported a net loss of $43.4M for fiscal year 2025.

Dividend & Returns

Outlook Therapeutics, Inc. (OTLK) had negative free cash flow of $56.4M in fiscal year 2025, likely due to heavy capital investments.

US Stock Screener

...

Outlook Therapeutics, Inc. (OTLK) 10-Year Financial Performance & Capital Metrics

OTLK • • Industrial / General

HealthcareBiotechnologyAutoimmune & Inflammatory DiseasesOphthalmology & Ocular Diseases

Revenue $1413.54B
EBITDA -$67061.67B -93675651.7%
Net Income -$62424.86B -82827746.4%
EPS (Diluted) -1.79 +55.9%
Gross Margin 4.05%
EBITDA Margin -4744.25%
Operating Margin -4744.25%
Net Margin -4416.22%
ROE -
ROIC -
Debt/Equity -
Interest Coverage -236.86 -942.9%

Technical Analysis

Key Insights

Based on financial data analysis

✓Strengths

No significant strengths identified

✗Weaknesses

✗Negative free cash flow
✗Weak momentum: RS Rating 4 (bottom 4%)
✗Shares diluted 37.3% in last year
✗Trading more than 30% below 52-week high
✗Low asset turnover indicates capital-intensive operations

Price & Volume

Loading chart...

Growth Metrics

Revenue CAGR

10Y249.36%

5Y-

3Y-

TTM-

Profit (Net Income) CAGR

10Y-

5Y-

3Y-

TTM53.81%

EPS CAGR

10Y-

5Y-

3Y-

TTM90.51%

ROCE

10Y Avg-71076.28%

5Y Avg-114371.18%

3Y Avg-342086.28%

Latest-

Peer Comparison

Ophthalmology & Ocular Diseases

Name	Market Cap	Current Price	P/E Ratio	Revenue Growth 1Y	Net Margin	ROE	FCF Yield	Debt/Equity
KPRXKiora Pharmaceuticals, Inc.	8.05M	2.19	2.52		22.47%	-38.12%	100%	0.00
KALAKALA BIO, Inc.	16.74M	0.60	-0.09		-141.11%	-388.29%		2.62
CLSDClearside Biomedical, Inc.	5.81M	1.11	-0.16	-79.77%	-7.81%
OTLKOutlook Therapeutics, Inc.	33.47M	0.52	-0.29		-25.93%
ADVMAdverum Biotechnologies, Inc.	96.26M	4.36	-0.66	-72.22%	-130.93%	-189.84%		1.30
IRDOpus Genetics, Inc.	143.45M	2.08	-0.97	-42.3%	-466.09%	-11.43%
SKYESkye Bioscience, Inc.	30.87M	0.96	-1.32			-156.01%		0.01
ALDXAldeyra Therapeutics, Inc.	265.32M	4.41	-4.69			-87.71%		0.22

Profit & Loss

	Sep 2016	Sep 2017	Sep 2018	Sep 2019	Sep 2020	Sep 2021	Sep 2022	Sep 2023	Sep 2024	Sep 2025
Sales/Revenue+	2.98M	3.81M	3.09M	8.15M	0	0	0	0	0	1.41T
Revenue Growth %	-0.43%	0.28%	-0.19%	1.64%	-1%	-	-	-	-	-
Cost of Goods Sold+	0	23.81M	18.5M	23.8M	554.07K	262.14K	204.69K	44.19K	113.86K	1.36T
COGS % of Revenue	-	6.25%	5.99%	2.92%	-	-	-	-	-	0.96%
Gross Profit+	0	0	0	-15.66M	-554.07K	-262.14K	-204.69K	-44.19K	-113.86K	57.2B
Gross Margin %	-	-	-	-1.92%	-	-	-	-	-	0.04%
Gross Profit Growth %	-	-	-	-	0.96%	0.53%	0.22%	0.78%	-1.58%	502420.66%
Operating Expenses+	21.56M	39.69M	32.73M	44.45M	34.42M	51.73M	62.87M	53.13M	71.7M	67.12T
OpEx % of Revenue	7.24%	10.41%	10.6%	5.46%	-	-	-	-	-	47.48%
Selling, General & Admin	21.56M	15.88M	14.23M	9.37M	9.97M	12.77M	20.74M	26.67M	29.94M	39.94T
SG&A % of Revenue	7.24%	4.17%	4.61%	1.15%	-	-	-	-	-	28.25%
Research & Development	32.76M	23.81M	18.5M	23.8M	26.34M	38.96M	42.33M	26.45M	41.76M	27.18T
R&D % of Revenue	10.99%	6.25%	5.99%	2.92%	-	-	-	-	-	19.23%
Other Operating Expenses	0	-23.81M	0	11.27M	-1.9M	0	-205K	0	0	0
Operating Income+	-51.35M	-35.88M	-29.64M	-36.3M	-36.84M	-51.73M	-63.07M	-53.13M	-71.7M	-67.06T
Operating Margin %	-17.23%	-9.41%	-9.6%	-4.46%	-	-	-	-	-	-47.44%
Operating Income Growth %	-0.1%	0.3%	0.17%	-0.22%	-0.01%	-0.4%	-0.22%	0.16%	-0.35%	-935269.02%
EBITDA+	-48.95M	-33.19M	-26.59M	-32.94M	-36.29M	-51.46M	-62.87M	-53.08M	-71.59M	-67.06T
EBITDA Margin %	-16.43%	-8.71%	-8.61%	-4.04%	-	-	-	-	-	-47.44%
EBITDA Growth %	-0.09%	0.32%	0.2%	-0.24%	-0.1%	-0.42%	-0.22%	0.16%	-0.35%	-936756.52%
D&A (Non-Cash Add-back)	2.39M	2.69M	3.05M	3.36M	554.07K	262.14K	204.69K	44.19K	113.86K	0
EBIT	-51.35M	-32.72M	-29.85M	-34.47M	-36.76M	-51.73M	-64.56M	-57.42M	-72.21M	0
Net Interest Income+	-1.85M	-5.63M	-3.89M	-3.47M	-1.76M	-936.13K	-1.49M	-1.56M	-2.25M	0
Interest Income	0	0	0	0	0	0	0	0	906.15K	-89.74B
Interest Expense	1.85M	5.63M	3.89M	3.47M	1.76M	936.13K	1.49M	1.56M	3.16M	283.13B
Other Income/Expense	-1.85M	-2.47M	-4.1M	-1.64M	-1.67M	-1.43M	-2.98M	-5.85M	-3.66M	3.08T
Pretax Income+	-53.2M	-38.35M	-33.74M	-37.94M	-38.51M	-53.16M	-66.05M	-58.98M	-75.36M	-63.98T
Pretax Margin %	-17.85%	-10.06%	-10.93%	-4.66%	-	-	-	-	-	-45.26%
Income Tax+	103K	501.5K	-3.65M	-3.41M	-3.27M	2K	2.8K	2.8K	2.8K	-1.55T
Effective Tax Rate %	1%	1.01%	0.89%	0.91%	0.92%	1%	1%	1%	1%	0.98%
Net Income+	-53.3M	-38.85M	-30.09M	-34.52M	-35.24M	-53.16M	-66.05M	-58.98M	-75.37M	-62.42T
Net Margin %	-17.89%	-10.19%	-9.74%	-4.24%	-	-	-	-	-	-44.16%
Net Income Growth %	-0.12%	0.27%	0.23%	-0.15%	-0.02%	-0.51%	-0.24%	0.11%	-0.28%	-828277.46%
Net Income (Continuing)	-53.3M	-38.85M	-30.09M	-34.52M	-35.24M	-53.16M	-66.05M	-58.98M	-75.37M	0
Discontinued Operations	0	0	0	0	0	0	0	0	0	0
Minority Interest	0	0	0	0	0	0	0	0	0	0
EPS (Diluted)+	-587.20	-288.00	-85.00	-39.60	-13.47	-6.96	-6.23	-4.72	-4.06	-1.79
EPS Growth %	-0.04%	0.51%	0.7%	0.53%	0.66%	0.48%	0.1%	0.24%	0.14%	0.56%
EPS (Basic)	-587.20	-267.20	-194.80	-39.60	-13.47	-6.96	-6.23	-4.72	-4.06	-1.79
Diluted Shares Outstanding	107.58K	150.26K	354.03K	909.59K	3.63M	7.63M	10.6M	12.51M	18.55M	25.48M
Basic Shares Outstanding	90K	150.14K	154K	909.59K	3.63M	7.63M	10.6M	12.51M	18.55M	34.8M
Dividend Payout Ratio	-	-	-	-	-	-	-	-	-	-

Balance Sheet

	Sep 2016	Sep 2017	Sep 2018	Sep 2019	Sep 2020	Sep 2021	Sep 2022	Sep 2023	Sep 2024	Sep 2025
Total Current Assets+	5.68M	3.9M	3.3M	13.5M	17.94M	21.51M	27.52M	30.98M	27.42M	17.39T
Cash & Short-Term Investments	2.35M	3.19M	1.72M	8.02M	12.54M	14.48M	17.4M	23.39M	14.93M	8.08T
Cash Only	2.35M	3.19M	1.72M	8.02M	12.54M	14.48M	17.4M	23.39M	14.93M	8.08T
Short-Term Investments	0	0	0	0	0	0	0	0	0	0
Accounts Receivable	0	0	0	0	0	0	0	0	0	1.49T
Days Sales Outstanding	-	-	-	-	-	-	-	-	-	384.99
Inventory	0	0	0	0	0	0	0	0	0	3.34T
Days Inventory Outstanding	-	-	-	-	-	-	-	-	-	898.39
Other Current Assets	0	0	0	1.7M	0	324	0	7.59M	12.49M	4.48T
Total Non-Current Assets+	18.03M	16.83M	18.98M	3.63M	1.79M	1.3M	1.01M	1.32M	1.41M	1.2T
Property, Plant & Equipment	16.96M	16.09M	18.49M	3.18M	494.24K	275.05K	70.36K	26.17K	274.64K	225.51B
Fixed Asset Turnover	0.18x	0.24x	0.17x	2.56x	-	-	-	-	-	6.27x
Goodwill	0	0	0	0	0	0	0	0	0	0
Intangible Assets	0	0	0	0	0	0	0	0	0	0
Long-Term Investments	216.09K	0	0	0	900K	853.66K	804.93K	793.93K	693.19K	0
Other Non-Current Assets	852.8K	740.36K	491.04K	457.48K	394.45K	174.59K	132.01K	501.3K	439.28K	969.71B
Total Assets+	23.71M	20.73M	22.28M	17.13M	19.73M	22.81M	28.53M	32.3M	28.82M	18.58T
Asset Turnover	0.13x	0.18x	0.14x	0.48x	-	-	-	-	-	0.08x
Asset Growth %	1.04%	-0.13%	0.07%	-0.23%	0.15%	0.16%	0.25%	0.13%	-0.11%	644764.77%
Total Current Liabilities+	20.44M	28.74M	32.04M	20.29M	15.89M	6.75M	19.73M	46.73M	42.55M	45.81T
Accounts Payable	5.07M	10.95M	3.61M	2.28M	2.39M	2.2M	3.49M	6.57M	7.97M	10.19T
Days Payables Outstanding	-	167.93	71.2	34.93	1.58K	3.06K	6.23K	54.31K	25.55K	2.74K
Short-Term Debt	5.2M	4.67M	17.86M	11.34M	3.66M	904.2K	10.92M	35.55M	29.44M	58.9B
Deferred Revenue (Current)	1000K	1000K	1000K	0	0	0	0	0	0	0
Other Current Liabilities	2.16M	3.69M	4.17M	5.56M	5.06M	2.83M	1.45M	1.83M	0	45.76T
Current Ratio	0.28x	0.14x	0.10x	0.67x	1.13x	3.19x	1.39x	0.66x	0.64x	0.38x
Quick Ratio	0.28x	0.14x	0.10x	0.67x	1.13x	3.19x	1.39x	0.66x	0.64x	0.31x
Cash Conversion Cycle	-	-	-	-	-	-	-	-	-	-1.46K
Total Non-Current Liabilities+	8.47M	22.72M	11.05M	7.61M	1.02M	11.45M	61.41K	6.22K	59.35M	4.96T
Long-Term Debt	2.23M	13.38M	98.49K	50.28K	904.2K	10.89M	0	0	0	188.8B
Capital Lease Obligations	320.74K	28.07K	3.45M	3.37M	42.48K	43.01K	4.27K	0	246.92K	0
Deferred Tax Liabilities	0	2.27M	3.45M	0	0	0	0	0	0	0
Other Non-Current Liabilities	761.33K	4.84M	4.74M	4.2M	70.77K	522.92K	57.14K	6.22K	59.1M	4.77T
Total Liabilities	28.91M	51.46M	43.09M	27.9M	16.91M	18.2M	19.79M	46.74M	101.9M	50.77T
Total Debt+	8.73M	18.42M	21.93M	14.95M	8.8M	11.9M	10.96M	35.56M	29.74M	247.7B
Net Debt	6.38M	15.23M	20.21M	6.93M	-3.74M	-2.57M	-6.44M	12.16M	14.81M	-7.84T
Debt / Equity	-	-	-	-	3.11x	2.58x	1.25x	-	-	-
Debt / EBITDA	-	-	-	-	-	-	-	-	-	-
Net Debt / EBITDA	-	-	-	-	-	-	-	-	-	-
Interest Coverage	-27.73x	-6.38x	-7.62x	-10.47x	-20.98x	-55.26x	-42.41x	-34.06x	-22.71x	-236.86x
Total Equity+	-5.2M	-30.73M	-20.81M	-10.77M	2.83M	4.61M	8.74M	-14.44M	-73.08M	-32.19T
Equity Growth %	0.78%	-4.91%	0.32%	0.48%	1.26%	0.63%	0.9%	-2.65%	-4.06%	-440464.22%
Book Value per Share	-48.34	-204.49	-58.78	-11.84	0.78	0.60	0.82	-1.15	-3.94	-999999.00
Total Shareholders' Equity	-5.2M	-30.73M	-20.81M	-10.77M	2.83M	4.61M	8.74M	-14.44M	-73.08M	-32.19T
Common Stock	228.03K	249.34K	722.2K	286.1K	1.27M	1.76M	2.27M	2.6M	239.06K	538.87B
Retained Earnings	-147.39M	-186.22M	-216.31M	-254.48M	-289.72M	-342.88M	-408.94M	-467.92M	-543.28M	-605.71T
Treasury Stock	0	0	0	0	0	0	0	0	0	0
Accumulated OCI	-5.96M	-8.64M	190.76M	0	-19.73T	-22.81T	417.67M	-32.3T	0	0
Minority Interest	0	0	0	0	0	0	0	0	0	0

Cash Flow

	Sep 2016	Sep 2017	Sep 2018	Sep 2019	Sep 2020	Sep 2021	Sep 2022	Sep 2023	Sep 2024	Sep 2025
Cash from Operations+	-45.48M	-15.51M	-33.04M	-32.29M	-31.79M	-54.25M	-56.67M	-42.97M	-68.79M	-51.83T
Operating CF Margin %	-15.26%	-4.07%	-10.7%	-3.96%	-	-	-	-	-	-36.67%
Operating CF Growth %	-0.66%	0.66%	-1.13%	0.02%	0.02%	-0.71%	-0.04%	0.24%	-0.6%	-753401.1%
Net Income	-53.33M	-38.85M	-46.11M	-34.52M	-35.24M	-53.16M	-66.05M	-58.98M	-75.37M	-62.42T
Depreciation & Amortization	2.39M	2.69M	-3.05M	3.36M	554.07K	262.14K	204.69K	44.19K	113.86K	117.05B
Stock-Based Compensation	12.45M	8.57M	1.99M	1.31M	2.81M	4.89M	7.71M	5.55M	5.39M	8.9T
Deferred Taxes	13.65K	-3.1M	20.15M	9.44M	2.24M	498.49K	0	0	0	0
Other Non-Cash Items	13.46K	4.01M	7.68M	1.31M	-881.33K	341.55K	3.15M	5.66M	4.09M	1.58T
Working Capital Changes	-7.02M	11.16M	-13.68M	-13.19M	-1.27M	-7.08M	-1.68M	4.75M	-3.02M	0
Change in Receivables	20K	0	0	0	0	0	0	0	0	-1.49T
Change in Inventory	-221.36K	0	0	0	0	0	0	0	0	-3.34T
Change in Payables	-5.33M	5.73M	-6.71M	-1.33M	-1.49M	-198.47K	1.3M	3.08M	1.39M	1.67T
Cash from Investing+	-1.1M	-292.09K	-2.78M	-437.31K	-900K	0	0	0	0	0
Capital Expenditures	-1.1M	-292.09K	-2.78M	-437.31K	0	0	0	0	0	0
CapEx % of Revenue	0.37%	0.08%	0.9%	0.05%	-	-	-	-	-	-
Acquisitions	-	-	-	-	-	-	-	-	-	-
Investments	-	-	-	-	-	-	-	-	-	-
Other Investing	0	0	0	0	900K	0	0	0	0	0
Cash from Financing+	39.86M	16.63M	34.35M	39.03M	37.21M	56.19M	59.59M	48.97M	60.33M	44.98T
Debt Issued (Net)	-	-	-	-	-	-	-	-	-	-
Equity Issued (Net)	-	-	-	-	-	-	-	-	-	-
Dividends Paid	0	-16.98B	-1.89T	0	0	0	0	0	0	0
Share Repurchases	-	-	-	-	-	-	-	-	-	-
Other Financing	-6.21K	16.99B	-1.09M	4.35K	1.14M	3.59M	-394.15K	-823.89K	0	44.98T
Net Change in Cash	-	-	-	-	-	-	-	-	-	-
Free Cash Flow+	-46.58M	-15.8M	-35.82M	-32.73M	-31.79M	-54.25M	-56.67M	-42.97M	-68.79M	-51.83T
FCF Margin %	-15.63%	-4.14%	-11.6%	-4.02%	-	-	-	-	-	-36.67%
FCF Growth %	-0.28%	0.66%	-1.27%	0.09%	0.03%	-0.71%	-0.04%	0.24%	-0.6%	-753401.1%
FCF per Share	-432.98	-105.13	-101.18	-35.98	-8.76	-7.11	-5.34	-3.44	-3.71	-999999.00
FCF Conversion (FCF/Net Income)	0.85x	0.40x	1.10x	0.94x	0.90x	1.02x	0.86x	0.73x	0.91x	0.83x
Interest Paid	2.06M	1.34M	109.98K	2.79M	913.97K	46.24K	1.56M	1.16M	475K	0
Taxes Paid	3K	1.5K	0	0	0	0	0	0	0	0

Key Ratios

Metric	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025
Return on Equity (ROE)	-	-	-	-	-1246.96%	-1430.46%	-990.02%	-	-	-
Return on Invested Capital (ROIC)	-3267.24%	-	-	-	-	-6926.23%	-2184.82%	-342086.28%	-	-
Gross Margin	-	-	-	-192.23%	-	-	-	-	-	4.05%
Net Margin	-1788.66%	-1019.12%	-974.48%	-423.82%	-	-	-	-	-	-4416.22%
Debt / Equity	-	-	-	-	3.11x	2.58x	1.25x	-	-	-
Interest Coverage	-27.73x	-6.38x	-7.62x	-10.47x	-20.98x	-55.26x	-42.41x	-34.06x	-22.71x	-236.86x
FCF Conversion	0.85x	0.40x	1.10x	0.94x	0.90x	1.02x	0.86x	0.73x	0.91x	0.83x
Revenue Growth	-42.9%	27.92%	-18.99%	163.8%	-100%	-	-	-	-	-

Frequently Asked Questions

Growth & Financials

Outlook Therapeutics, Inc. (OTLK) reported $1.7M in revenue for fiscal year 2025. This represents a 81% decrease from $9.1M in 2014.

Outlook Therapeutics, Inc. (OTLK) grew revenue by 0.0% over the past year. Growth has been modest.

Outlook Therapeutics, Inc. (OTLK) reported a net loss of $43.4M for fiscal year 2025.

Dividend & Returns

Outlook Therapeutics, Inc. (OTLK) had negative free cash flow of $56.4M in fiscal year 2025, likely due to heavy capital investments.